Simon C. Lowry - 15 Dec 2024 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
SVP, R&D, CMO
Signature
/s/ Jessica Perl, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
15 Dec 2024
Net transactions value
$0
Form type
4
Filing time
17 Dec 2024, 17:44:01 UTC
Previous filing
21 Nov 2024
Next filing
10 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Award $0 +29,482 $0.000000 29,482 15 Dec 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EBS Employee Stock Option (Right to buy) Award $0 +40,499 $0.000000 40,499 15 Dec 2024 Common Stock 40,499 $8.48 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
F2 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.